Id |
Subject |
Object |
Predicate |
Lexical cue |
T208 |
0-100 |
Sentence |
denotes |
Table 2 Antiviral treatment protocols for coronavirus disease 2019 according to clinical condition. |
T209 |
101-227 |
Sentence |
denotes |
Antiviral Treatment Mild Respiratory Illness with Clinical Risk Factors Mild Pneumonia Moderate Pneumonia Severe Pneumonia |
T210 |
228-259 |
Sentence |
denotes |
No 2 (13.3%) 1 (6.7%) NR NR |
T211 |
260-285 |
Sentence |
denotes |
H1 5 (33.3%) NR NR NR |
T212 |
286-310 |
Sentence |
denotes |
H2 1 (6.7%) NR NR NR |
T213 |
311-336 |
Sentence |
denotes |
LR1 1 (6.7%) NR NR NR |
T214 |
337-379 |
Sentence |
denotes |
H1 + A 3 (20.0%) 4 (26.6%) 1 (6.7%) NR |
T215 |
380-421 |
Sentence |
denotes |
H2 + A 1 (6.7%) 2 (13.3%) 1 (6.7%) NR |
T216 |
422-463 |
Sentence |
denotes |
H3 + A NR 1 (6.7%) 2 (13.3%) 1 (6.7%) |
T217 |
464-498 |
Sentence |
denotes |
H4 + A NR NR 1 (6.7%) 1 (6.7%) |
T218 |
499-537 |
Sentence |
denotes |
H1 + LR1 2 (13.3%) 3 (20.0%) NR NR |
T219 |
538-582 |
Sentence |
denotes |
H1 + LR2 NR 1 (6.7%) 5 (33.3%) 3 (20.0%) |
T220 |
583-613 |
Sentence |
denotes |
H3 + LR1 NR NR 1 (6.7%) NR |
T221 |
614-658 |
Sentence |
denotes |
H3 + LR2 NR 3 (20.0%) 1 (6.7%) 4 (26.6%) |
T222 |
659-693 |
Sentence |
denotes |
H1 + A + LR1 NR NR 1 (6.7%) NR |
T223 |
694-728 |
Sentence |
denotes |
H1 + A + LR2 NR NR 1 (6.7%) NR |
T224 |
729-763 |
Sentence |
denotes |
H3 + A + LR1 NR NR 1 (6.7%) NR |
T225 |
764-799 |
Sentence |
denotes |
H3 + A + LR2 NR NR NR 6 (40.0%) |
T226 |
800-1138 |
Sentence |
denotes |
H1: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/12 h (day 2 to 5) (regimen 1); H2: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/8 h (day 2 to 5) (regimen 2); H3: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/12 h (day 2 to 7–10) (regimen 3); H4: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/8 h (day 2 to 7–10) (regimen 4); A: |
T227 |
1139-1352 |
Sentence |
denotes |
Azithromycin 500 mg/24 h (day 1) + 250 mg/24 h (day 2 to 5); LR1: lopinavir/ritonavir 200/50 mg/12 h (day 1 to 5) (regimen 1); LR2: lopinavir/ritonavir 200/50 mg/12 h (day 1 to 7–10) (regimen 2); NR: not reported. |